IMMUNITYBIO, INC. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/ddf8382d-5348-40e2-9b96-16a8ca57338f/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $113.3M | 2025-01-01 – 2025-12-31 | evidence 0001326110-26-000030 |
| FY 2024 | $14.7M | 2024-01-01 – 2024-12-31 | evidence 0001326110-25-000033 |
| FY 2023 | $622.0k | 2023-01-01 – 2023-12-31 | evidence 0001326110-25-000033 |
| FY 2022 | $240.0k | 2022-01-01 – 2022-12-31 | evidence 0001326110-25-000033 |
| FY 2021 | $934.0k | 2021-01-01 – 2021-12-31 | evidence 0001326110-22-000011 |
| FY 2020 | $605.0k | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-126681 |
| FY 2019 | $2.2M | 2019-01-01 – 2019-12-31 | evidence 0001193125-21-126681 |
| FY 2018 | $47.0k | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007562 |
| FY 2017 | $45.0k | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005290 |
| FY 2016 | $44.0k | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-004430 |
| FY 2015 | $236.0k | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-015596 |
| FY 2014 | $641.0k | 2014-01-01 – 2014-12-31 | evidence 0001564590-16-015596 |
| FY 2013 | $600.0k | 2013-01-01 – 2013-12-31 | evidence 0001564590-16-015596 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
IMMUNITYBIO, INC. — all facts · Net Income · Operating Income